Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02223247 | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | completed | Phase 1 | 180 | Sagimet Biosciences Inc.INDUSTRY | 2 | Aug 14, 2017 | clinicaltrials |
| NCT03238144 | Tissue Stresses of Cancer (Force Horizon 2020) | unknown | Phase 1 / Phase 2 | 200 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Aug 3, 2017 | clinicaltrials |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | completed | Phase 1 | 39 | Seagen Inc.INDUSTRY | 2 | Jun 28, 2017 | clinicaltrials |
| NCT00536835 | Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma | completed | Phase 1 | 41 | GlaxoSmithKlineINDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02155582 | Copanlisib Pharmacodynamic Study | completed | Phase 1 | 63 | BayerINDUSTRY | 3 | Jun 16, 2017 | clinicaltrials |
| NCT00920803 | A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases | completed | Phase 1 | 9 | Sirtris, a GSK CompanyINDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) | completed | Phase 1 / Phase 2 | 12 | Virttu Biologics LimitedINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT02490475 | A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors | completed | Phase 1 | 19 | Hoffmann-La RocheINDUSTRY | 2 | May 17, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | terminated | Phase 1 | 71 | GlaxoSmithKlineINDUSTRY | 6 | May 15, 2017 | clinicaltrials |
| NCT01355302 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT01138033 | Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | completed | Phase 1 | 74 | GlaxoSmithKlineINDUSTRY | 3 | May 11, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | unknown | Phase 1 | 20 | University of NottinghamOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01949545 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | completed | Phase 1 | 46 | AmgenINDUSTRY | 4 | May 2, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT00934856 | A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 98 | Hoffmann-La RocheINDUSTRY | 4 | Apr 6, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT02379741 | ADC-1013 First-in-Human Study | completed | Phase 1 | 24 | Alligator Bioscience ABINDUSTRY | 3 | Mar 27, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01268163 | The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer | completed | Phase 1 | 32 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 2 | Mar 20, 2017 | clinicaltrials |
| NCT01608009 | [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer(PAZPET-1) | completed | Phase 1 | 16 | Imperial College LondonOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01449370 | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | completed | Phase 1 | 125 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Mar 9, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01489826 | A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours | completed | Phase 1 | 40 | e-Therapeutics PLCINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | terminated | Phase 1 | 21 | Verastem, Inc.INDUSTRY | 2 | Jan 30, 2017 | clinicaltrials |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | terminated | Phase 1 | 75 | Verastem, Inc.INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT00755885 | Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 77 | Cancer Research UKOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT01980667 | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | completed | Phase 1 | 41 | PharmaMarINDUSTRY | 2 | Jan 26, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT02442063 | Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | completed | Phase 1 | 15 | BayerINDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00623870 | A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. | completed | Phase 1 | 116 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT00773526 | A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00854152 | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 121 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00882674 | A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer | completed | Phase 1 | 8 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01148758 | A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | completed | Phase 1 | 22 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01493336 | A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours | completed | Phase 1 | 37 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT02721784 | Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy(SMART) | unknown | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT02647684 | Triple P for Parents of Children With a Diagnosis of Cancer | completed | Phase 1 / Phase 2 | 4 | University of ManchesterOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT00260364 | Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer(TARGET) | completed | Phase 1 / Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 5 | Oct 13, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials